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Objective: To evaluate the feasibility of using magnetic iron oxide (Fe3O4)-dextran-anti-β-human   
chorionic gonadotropin (HCG) nanoparticles as a gene vector for cellular transfections.
Study design: Fe3O4-dextran-anti-β-HCG nanoparticles were synthesized by chemical copre-
cipitation. The configuration, diameter, and iron content of the nanoparticles were detected by 
transmission electron microscopy (TEM), light scatter, and atomic absorption spectrophotometry. 
A3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide assay was used to evaluate 
the cytotoxicity of Fe3O4-dextran-anti-β-HCG nanoparticles. Enzyme-linked immunosorbent 
assay and indirect immunofluorescence were used to evaluate immunoreactivity. The efficiency 
of absorbing DNA and resisting deoxyribonuclease I (DNase I) digestion when bound to Fe3O4-
dextran-anti-β-HCG nanoparticles was examined by agarose gel electrophoresis. The ability of 
Fe3O4-dextran-anti-β-HCG nanoparticles to absorb heparanase antisense oligodeoxynucleotides 
(AS-ODN) nanoparticles in different cell lines was evaluated by flow cytometry. The tissue 
distribution of heparanase AS-ODN magnetic nanoparticles in choriocarcinoma tumors trans-
planted in nude mice was detected by atomic absorption spectrophotometry.
Results: TEM demonstrated that the shape of nanoparticles is irregular. Light scatter 
revealed nanoparticles with a mean diameter of 75.5 nm and an iron content of 37.5 µg/mL. 
No cytotoxicity was observed when the concentration of Fe3O4-dextran-anti-β-HCG nanopar-
ticles was ,37.5 µg/mL. Fe3O4-dextran nanoparticles have a satisfactory potential to combine 
with β-HCG antibody. Agarose gel electrophoresis analysis of binding experiments showed 
that after treatment with sodium periodate, Fe3O4-dextran-anti-β-HCG nanoparticles have a 
satisfactory potential to absorb DNA, and the protection experiment showed that nanoparticles 
can effectively protect DNA from DNase I digestion. Aldehyde Fe3O4-dextran-anti-β-HCG 
nanoparticles can transfect reporter genes, and the transfection efficiency of these nanoparticles 
is greater than that of liposomes (P , 0.05). Fe3O4-dextran-anti-β-HCG nanoparticles can 
  concentrate in choriocarcinoma cells and in transplanted choriocarcinoma tumors.
Conclusions: The results confirm that Fe3O4-dextran-anti-β-HCG nanoparticles have potential 
as a secure, effective, and choriocarcinoma-specific targeting gene vector.
Keywords: magnetic nanoparticles, Fe3O4-dextran-anti-β-HCG, choriocarcinoma, targeting 
vector, gene vector
Gene therapy modifies gene expression for therapeutic gain. Over the last two decades, 
gene therapy research has moved from preclinical to clinical studies for many diseases, 
ranging from single-gene disorders, such as cystic fibrosis and Duchene muscular 
dystrophy, to multigenic diseases, such as cancer.1International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In most gene therapy studies, a ‘corrected’ therapeutic 
gene is inserted into the genome to replace an ‘abnormal’ 
disease-causing gene. A vector (ie, a carrier) must be used 
to deliver the therapeutic gene to the patient’s target cells. 
The most common vectors are viruses, but viral vectors are 
often toxic or immunogenic and make it difficult to verify 
successful infection of the targeted cells.
An ideal gene delivery system should be stable, biocom-
patible, nontoxic, cost-effective, and capable of transferring 
exogenous, highly anionic genetic materials (ie, DNA, 
antisense oligodeoxynucleotides [AS-ODNs], short inter-
fering ribonucleic acids [RNAs]) into tissue-specific sites. 
A primary goal of gene therapy is to target vectors and the 
genes of interest efficiently to specific cell types. Recent 
advances in nanoparticle technology have yielded new types 
of gene vectors.
Magnetic iron oxide (Fe3O4) nanoparticles are considered 
ideal gene vectors because they are simple to manufacture, 
have diameters of ,10 nm, are able to absorb a significant 
amounts of DNA, demonstrate limited cellular toxicity, 
and can be guided to specific sites via magnets. In addi-
tion, to improve biocompatibility, iron oxide nanoparticles 
can be embedded in various macromolecules, such as 
polysaccharides and proteins. However, human organs such 
as liver, spleen, and lymph (among others) are infused with 
a reticuloendothelial system and have the ability to pas-
sively absorb nanoparticles through phagocytosis. Because 
β-human chorionic gonadotropin (HCG) is expressed only 
in choriocarcinomas, anti-β-HCG monoclonal antibody were 
attached to magnetic particles to allow the nanoparticles to 
target the tissues of interest.
In this study, nanometer-sized dextran-coated iron oxide 
particles modified with an anti-β-HCG monoclonal anti-
body were synthesized, and the feasibility of using Fe3O4- 
dextran-anti-β-HCG as a gene vector was tested.
Material and methods
Materials
All reagents used for nanoparticle synthesis were commercial 
products. Dextran (40,000 MW; T-40), deoxyribonuclease 
I (DNase I), and bovine serum albumin (BSA) were pur-
chased from Sigma-Aldrich Corporation (St. Louis, MO). 
Lipofectamine2000 was purchased from Invitrogen 
Corporation (Carlsbad, CA). Mouse anti-human β-HCG 
monoclonal antibody was purchased from Wolwo Biotech-
nology (Shanghai, China). Goat anti-mouse immunoglobulin 
G/fluorescein isothiocynate (IgG/FITC) and goat anti-
mouse IgG/horseradish peroxidase (HRP) were purchased 
from Shiruike Biotechnology (Shanghai, China). DNA 
marker ΦX174-Hinc II digest was obtained from TaKaRa 
Corporation (Shiga, Japan). Analytical grade chemicals 
(ie, FeCl3⋅6H2O, and FeCl2⋅4H2O) were obtained from local 
suppliers. All aqueous solutions were prepared using distilled 
water and filtered through 0.22-mm membranes.
JEG-3 and JAR human choriocarcinoma cell lines were 
purchased from American Type Culture Collection (ATCC, 
Manassas, VA). RL95-2, Hela, HepG2, and Lovo cell lines 
were supplied by the cell center of Central South University 
(Changsha, China).
Female BALB/c nude mice (4 weeks old) were 
supplied and fed by the animal division of Central South 
University.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
AS-ODN was synthesized by Shanghai Sangon Biological 
Engineering Technology and Services Company Ltd (Shanghai, 
China). The GAPDH AS-ODN sequence was 5′-GAC CTT 
CAC CAT CTT GTC TA-3′, with a 5′ terminal FITC group 
including some phosphorothioated nucleotides. Oligonucle-
otides were diluted to 100 µmol/L and stored at −20°C.
Cell culture studies
JEG-3, JAR, RL95-2, Hela, HepG2, and Lovo cell lines were 
cultured in Roswell Park Memorial Institute (RPMI) medium 
(Invitrogen) supplemented with 10% fetal calf serum.
Preparation and physical 
characterization of magnetic Fe3O4-
dextran-anti-β-HCG nanoparticles
Preparation of nanoparticles
Fe3O4-dextran-anti-β-HCG nanoparticles were prepared as 
described by Xia et al.2 Dextran (5 g), FeCl3⋅6H2O (0.552 g), 
and FeCl2⋅4H2O (0.45 g) were dispersed in 10 mL water. 
The mixture was titrated to alkaline by 10 mL of 5 mol/L 
ammonia and quickly heated to 60°C, with magnetic 
stirring. After 30 min, the suspension was neutralized with 
acetic acid. Aggregates were removed by centrifugation 
for 10 min. The dextran-coated iron oxide nanoparticles 
were separated from unbound dextran by magnetic separa-
tor and eluted with 10 mL sodium acetate (pH 6.5). The 
dextran-coated iron oxide suspension was oxidized with 
sodium periodate (NaIO4) with magnetic stirring in the dark 
at 4°C for 1 h to drive aldehyde termination. The solution 
was dialyzed while under magnetic stirring. Then, 100 µg 
mouse anti-human β-HCG monoclonal antibody was mixed 
with 1 mL aldehyde dextran-coated iron oxide nanoparticle 
solution. The solution was kept in the dark at 4°C for 24 h International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and then blocked by 50 µL 10% wt/vol BSA. To improve 
stability, 1 mol/L sodium borohydride (NaBH4) was added 
to the compound at 4°C for 3 h and stirred. Finally, the sus-
pension was centrifuged for 20 min at 13,000 rpm, repeated 
three times. The final product was dispersed in 1 mL sodium 
perborate (NaBO3) (pH 8.5) and preserved at 4°C.
Morphological determination
The Fe3O4-dextran-anti-β-HCG nanoparticles solution was 
titrated with a copper wire. After drying, morphological 
structure was determined by CM120 transmission electron 
microscopy (TEM) (Philips, Eindhoven, The Netherlands).
effective diameter determination
Fe3O4-dextran-anti-β-HCG nanoparticles were dispersed 
in high-purity water using ultrasound vibration and placed 
into a color matching cup. The effective diameter was deter-
mined using a Mastersizer 2000 Laser Particle Size Analyzer 
(Malvern Instruments, Malvern, UK).
evaluation of iron content
Iron content was determined by atomic absorption Spectra-30 
Photometer (Varian Instruments, Palo Alto, CA).
Effect of Fe3O4-dextran-anti-β-HCG 
nanoparticles on cells
Toxicity of Fe3O4-dextran-anti-β-hcg 
nanoparticle
JEG-3 cells were seeded in 96-well plates (5000 cells/
well) in media containing various concentrations of Fe3O4-
dextran-anti-β-HCG nanoparticles (0, 18.75, 30.0, 37.5, 
56.25, and 75 µg/mL). After 24 h, MTT (Sigma) was added 
and incubated for 4 h. Cells were washed with phosphate-
buffered saline (PBS) and stained with purple formazan 
solubilized in 100% dimethyl sulfoxide. Absorbance was read 
at 570 nm. The inhibitory rate of Fe3O4-dextran-anti-β-HCG 
nanoparticles was calculated as (OD570 control group − OD570 
experimental group/OD570 control group).
Immunological features of Fe3O4-
dextran-anti-β-HCG nanoparticles
enzyme-linked immunosorbent assays for 
Fe3O4-dextran-anti-β-hcg nanoparticles
JEG-3 cells were seeded in 96-well plates (5000 cells/well). 
Aldehyde Fe3O4-dextran-anti-β-HCG nanoparticle, nonalde-
hyde Fe3O4-dextran-anti-β-HCG nanoparticle (anti-β-HCG 
monoclonal antibody was mixed with nonoxidized 
dextran-coated iron oxide nanoparticles), and anti-β-HCG 
monoclonal antibody solutions (at 10, 50, 80 100, or 150 µg/mL 
anti-β-HCG monoclonal antibody) were titrated into the wells 
(100 µL/well) which were incubated for 1 h at 37°C. Dextran-
coated iron oxide nanoparticles served as a control. After 
washing two times, goat antimouse IgG/HRP (diluted 1:2000) 
was added into each well and wells were incubated at 37°C 
for 1 h. Solutions were prepared by addition of 3,3′,5,5′-
tetramethylbenzidine peroxidase, for 15–20 min at 37°C, and 
the reactions were stopped by addition of 2M H2SO4 (50 µL/
well). Optical density (OD) was read at 492 nm immediately 
after stopping the reaction in an ELX808 Ultra Microplate 
Reader (Bio-Tek, Winooski, VT). All samples were prepared 
in triplicate. The percent transfection was calculated as OD 
anti-β-HCG monoclonal antibody activity of aldehyde or 
nonaldehyde Fe3O4-dextran-anti-β-HCG nanoparticle/OD 
anti-β-HCG monoclonal antibody × 100.
Indirect immunofluorescence assay for 
Fe3O4-dextran-anti-β-hcg nanoparticles
JEG-3 cells were seeded onto slides and incubated in cul-
ture dishes for 48 h. The cells were then incubated with 
aldehyde Fe3O4-dextran-anti-β-HCG nanoparticle solution, 
nonaldehyde Fe3O4-dextran-anti-β-HCG nanoparticle solu-
tion, and anti-β-HCG monoclonal antibody solution which 
contained 100 µg/mL anti-β-HCG monoclonal antibody at 
4°C for 30 min. JEG-3 cells were then cultured for another 
30 min, fixed using paraformaldehyde, treated with trini-
trotoluene, and incubated with goat antimouse IgG/FITC at 
37°C for 30 min. Slides were sealed with glycerin, and images 
were observed at 400 by fluorescence microscopy (Axiolab; 
Carl Zeiss Shanghai Co Ltd, Guangzhou, China).
Evaluation of Fe3O4-dextran-anti- 
β-HCG nanoparticles as gene vectors
Preparation of Fe3O4-dextran-anti- 
β-hcg-gAPDh As-ODN mixtures
Mouse antihuman β-HCG monoclonal antibody (10 µg) and 
GAPDH AS-ODN (20 µL in 100 µmol/L) were mixed with 
100 µL aldehyde or nonaldehyde dextran-coated iron oxide 
nanoparticles. Following incubation in the dark at 4°C for 24 h, 
the mixture was blocked by 5 µL of 10% wt/vol bovine serum 
albumin (BSA). To improve stability, 1-mol/L NaBH4 was added 
to the mixture at 4°C and stirred for 3 h. Finally, the suspen-
sion was   centrifuged for 20 min at 13,000 rpm, the supernatant 
removed, and dispersed again with 100 µL NaBO3 (pH 8.5). This 
  centrifugation and wash step were repeated three times.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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electrophoretic assessment  
of nanoparticle complexes
Aldehyde Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN, 
nonaldehyde Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN, 
and GAPDH AS-ODN (20 µmol/L) were separated by gel 
electrophoresis and visualized by ethidium bromide staining. 
Samples were analyzed using GeneScan Analysis software 
and GeneScan Genotyper software (Applied Biosystems, 
Foster City, CA). Aldehyde Fe3O4-dextran-anti-β-HCG 
nanoparticle solution served as a control.
Fe3O4-dextran-anti-β-hcg nanoparticles 
protect DNA from DNase I
Aldehyde Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN, 
nonaldehyde Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN, 
and GAPDH AS-ODN (20 µmol/L) were subjected to 
DNase I at 37°C for 1 h. Products were identified by gel 
electrophoresis and visualized by ethidium bromide staining. 
Results were obtained by GeneScan Analysis software and 
GeneScan Genotyper software (Applied Biosystems).
Efficiency of Fe3O4-dextran-anti-β-hcg 
nanoparticles as gene vector
JEG-3 cells were seeded in six-well plates in culture media 
containing Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN/
FITC compounds (20-µmol/L AS-ODN, 37.5-µg/mL Fe3+), 
Fe3O4-dextran-anti-β-HCG nanoparticles (37.5-µg/mL Fe3+), 
GAPDH AS-ODN/FITC (20-µmol/L AS-ODN), and 
liposome-GAPDH AS-ODN/FITC compounds (20-µmol/L 
AS-ODN). Pure culture media served as controls. Following 
transfection, cells were cultured for 24 h, digested with trypsin 
(0.25%), and washed three times with PBS (centrifuged for 
5 min at 1000 rpm to remove free fluorescence). Fluorescence 
intensity (106 cells) was measured by flow cytometry.
Absorption of Fe3O4-dextran-anti-β-hcg-
gAPDh As-ODN in different cell type
JEG-3, JAR, RL95-2, Hela, HepG2, and Lovo cells were 
seeded in six-well plates and transfected with Fe3O4-
dextran-anti-β-HCG-GAPDH AS-ODN/FITC compounds 
(20-µmol/L AS-ODN, 37.5-µg/mL Fe3+). Fluorescence 
intensity was measured using flow cytometry as described.
Distribution of Fe3O4-dextran-anti- 
β-hcg nanoparticles in nude mice
Cultured JEG-3 cells were harvested and resuspended in 
naive RPMI medium at 4–6 × 106 cells/mL, and 100 µL 
were immediately injected into the flank of eight nude 
mice. When tumor diameter reached ∼8–10 mm, Fe3O4-
dextran-anti-β-HCG nanoparticle solution (0.5 mL/mouse, 
1.5 mg/mL Fe3+) was injected into tail veins of eight mice; 
the hypodermal tumor of four mice (group I) were treated 
with a 12,000 gauss, 1-cm-diameter magnetic stick, and four 
mice (group II) were not treated. Dextran-coated iron oxide 
nanoparticle solution (0.5 mL/mouse, 1.5 mg/mL Fe3+) was 
also injected to four mice (group III) through the tail vein. 
After 30 min, 100 mg of tissue was harvested from heart, 
liver, spleen, lung, kidney, and choriocarcinoma hypoder-
mal tumors of all mice and digested (nitric acid:perchloric 
acid, 4:1). Iron content was measured by atomic absorption 
using a Spectra-30 Photometer.
Statistical analysis
Statistical significance was assessed using Student’s t-test or 
analysis of variance (ANOVA) (one-way ANOVA followed 
by Dunnett’s test) using SAS (SAS Institute, Cary, NC). 
Differences between means were considered significant at 
P , 0.05.
Results
Morphology and diameter of  
Fe3O4-dextran-anti-β-hcg nanoparticles
Fe3O4-dextran-anti-β-HCG nanoparticle solution is 
atramentous and transparent. Using TEM, nanoparticles of 
uniform size and irregular shape (Figure 1) were observed. The 
average diameter was 75.5 nm (range = 33.7–84.7 nm).
The iron content of Fe3O4-dextran-anti-β-HCG nano-
particles is 37.5 µg/mL.
Figure  1  Transmission  electron  micrograph  of  magnetic  iron  oxide  (Fe3O4)-
dextran-anti-β-hcg nanoparticles.
Abbreviations: hcg, human chorionic gonadotropin.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Inhibitory rate of Fe3O4-dextran-anti-β-hcg nanoparticle to Jeg-3 cells
Control group 18.75 (μg/mL) 30 (μg/mL) 37.5 (μg/mL) 56.25 (μg/mL) 75 (μg/mL)
A570 0.374 ± 0.025 0.372 ± 0.031 0.368 ± 0.027 0.361 ± 0.023 0.310 ± 0.037 0.293 ± 0.034
Inhibitory rate (%) 0 0.5 1.6 3.5 17.1 21.7
Abbreviations: hcg, human chorionic gonadotropin; Fe3O4, magnetic iron oxide.
Toxicity of Fe3O4-dextran-anti-β-hcg 
nanoparticles
As shown in Table 1, the inhibitory rate of nanoparticles at 
56.25 and 75 µg/mL is higher than control (P , 0.05). In 
contrast, a significant difference was not observed between 
nanoparticle concentrations at 18.75, 30, or 37.5 µg/mL and 
control (P . 0.05).
enzyme-linked immunosorbent assay for 
Fe3O4-dextran-anti-β-hcg nanoparticles
The transfection efficiency of anti-β-HCG monoclonal 
antibody activity in aldehyde Fe3O4-dextran-anti-β-HCG 
nanoparticle is .85%, whereas the transfection rate of 
anti-β-HCG monoclonal antibody activity in nonaldehyde 
Fe3O4-dextran-anti-β-HCG nanoparticle is ∼13% (P , 0.05) 
(Table 2).
Indirect immunofluorescence assay for 
Fe3O4-dextran-anti-β-hcg nanoparticles
Upon treatment with aldehyde Fe3O4-dextran-anti-β-HCG/
FITC nanoparticle solution, JEG-3 cells surrounded by fluo-
rescent (Figure 2A) were noted. A similar result was obtained 
with anti-β-HCG antibody (Figure 2B). Together, these data 
suggest that Fe3O4-dextran-anti-β-HCG nanoparticles bind 
with JEG-3 cells in a manner similar to anti-β-HCG antibody. 
Nonaldehyde Fe3O4-dextran-anti-β-HCG/FITC nanoparticles 
cannot combine with JEG-3 cells because there are no 
  fluorescent substances on JEG-3 cells (Figure 2C).
Fe3O4-dextran-anti-β-hcg  
nanoparticles as a gene vector
DNA in nonaldehyde Fe3O4-dextran-anti-β-HCG-GAPDH 
AS-ODN complexes migrate in agarose gels (Figure 3, 
third track), similar to migration of simple GAPDH 
AS-ODN (second track). This indicates that nonaldehyde 
Fe3O4-dextran nanoparticles cannot combine with GAPDH 
AS-ODN. After oxidization with NaIO4, aldehyde Fe3O4-
dextran nanoparticles are able to combine with GAPDH 
AS-ODN, so the DNA in aldehyde Fe3O4-dextran-anti- 
β-HCG-GAPDH AS-ODN complexes is retained in the load-
ing well (Figure 3, fourth track). On the other hand, there 
is no DNA in   Fe3O4-dextran-anti-β-HCG nanoparticles, 
hence the compounds migrate either in the fifth track or in 
the loading well.
Fe3O4-dextran-anti-β-hcg nanoparticles 
protect DNA from DNase I
The absence of a DNA band in second and third tracks 
indicates that the DNA in nonaldehyde Fe3O4-dextran-anti-
β-HCG-GAPDH AS-ODN complexes and simple GAPDH 
AS-ODN is digested by DNase I. In contrast, DNA in the 
aldehyde Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN 
complexes is retained in the loading well of fourth track, 
indicating that Fe3O4-dextran-anti-β-HCG nanoparticles 
protect DNA from DNase I digestion (Figure 4).
Efficiency of Fe3O4-dextran-anti-β-hcg 
nanoparticle as gene vector
The fluorescence intensity of group IV in JEG-3 cells is higher 
than that of groups I, II, III, and V (P , 0.05) (Table 3), 
indicating that Fe3O4-dextran-anti-β-HCG nanoparticles are 
effective as a gene vector. Interestingly, the efficiency of gene 
transfection using Fe3O4-dextran-anti-β-HCG nanoparticles is 
higher than that observed using liposomes (P , 0.05).
Absorption of Fe3O4-dextran-anti-β-
hcg-gAPDh As-ODN in different cells
The fluorescence intensity in JEG-3 and JAR cells is clearly 
higher than that observed in RL95-2, Hela, HepG2, and 
Lovo (P , 0.05) (Table 4), while there is little difference 
between the fluorescence intensity of JEG-3 and JAR cells 
(P . 0.05). These results indicate that Fe3O4-dextran-
  anti-β-HCG nanoparticles are more readily absorbed by 
  choriocarcinoma cells.
Distribution of Fe3O4-dextran-anti- 
β-hcg nanoparticles in nude mice
In groups I and II, iron content in choriocarcinoma hypodermal 
tumors was highest in heart, liver, spleen, lung, and kidney 
(P , 0.05). At the same time, it was found that Fe3+ content 
in choriocarcinoma hypodermal tumors of group I was higher 
than that of group II (P , 0.05). In group III, the iron content 
in choriocarcinoma hypodermal tumors is less than that in liver 
or spleen (P , 0.05). These results indicate that when modified International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Transfection efficiency of anti-β-hcg monoclonal antibody bound to nanoparticle
Antibody 
concentration 
(μg/mL)
Anti-β-HCG 
antibody 
(OD data)
Aldehyde 
nanoparticle 
(OD data)
Preservation 
rate (%)
Nonaldehyde 
nanoparticle 
(OD data)
Preservation 
rate (%)
150 0.441 0.385 87.3 0.058 13.2
100 0.372 0.341 91.7 0.050 13.4
80 0.316 0.282 89.2 0.041 13.0
50 0.281 0.253 90.0 0.039 13.9
10 0.227 0.208 91.6 0.031 13.7
Abbreviations: hcg, human chorionic gonadotropin; OD, optical density.
by β-HCG monoclonal antibody, Fe3O4 nanoparticles are able 
to target choriocarcinoma tumors and that magnetic fields can 
strengthen the targeting efficiency (Table 5).
Discussion
Gene therapy is the insertion of genes into an individual’s 
cells and tissues to treat a disease. For hereditary diseases, the 
defective mutant allele is replaced with a functional allele. 
Antisense therapy is not strictly a form of gene therapy, but it is 
a genetically mediated therapy and is often used together with 
other methods. Using AS-ODNs to downregulate specific gene 
products requires oligonucleotides to enter cells and hybridize 
to the target messenger RNA present in the cytoplasm and/or 
nucleus.3 Nevertheless, the poor ability of oligonucleotides to 
cross the cell membrane and the degradation of oligonucleotides 
by DNase I greatly limit their potency. Therefore, it is necessary 
to identify a safe, effective, and stable gene vector.4,5
The development of nanoparticle technology provides a new 
type of gene vector. Nanoparticles possess several advantages as 
gene vectors:6 1) they are not biologic materials, so they should 
not induce immune responses; 2) unlike viral carriers, they have 
AB
C
Figure 2 Immunofluorescence staining of A) aldehyde Fe3O4-dextran-anti-β-hcg 
nanoparticles, B) anti-β-hcg antibody, and C) nonaldehyde Fe3O4-dextran-anti-
β-hcg nanoparticle. 
Abbreviations: Fe3O4, magnetic iron oxide; hcg, human chorionic gonadotropin.
limited genotoxicity and cytotoxicity; 3) they can mediate the 
insertion of foreign genes into DNA of host chromosomes, and 
as a result, foreign genes are stably expressed; 4) they can protect 
foreign genes from complement and host enzymes; and 5) they 
can counteract or kill some viruses. With these advantages, 
nanoparticles have promise as gene vectors.
The feasibility and superiority of Fe3O4-dextran-anti-
β-HCG nanoparticles as gene vector are discussed in the 
next section.
Preparation and characterization of 
Fe3O4-dextran-anti-β-hcg nanoparticles
Dextran, FeCl3, and FeCl2 precipitate together under alkaline 
conditions. As a result, nanometer-sized dextran-coated 
iron oxide particles may be synthesized. The surface of 
dextran contains many hydroxyl groups. Once oxidized by 
NaIO4, these hydroxyl groups can transform to aldehyde 
1234 5
Figure 3 electrophoresis of simple gAPDh As-ODN (second track), nonaldehyde 
Fe3O4-dextran-anti-β-hcg-gAPDh As-ODN (third track), aldehyde Fe3O4-dextran-
anti-β-hcg-gAPDh  As-ODN  (fourth  track),  and  Fe3O4-dextran-anti-β-hcg 
nanoparticles (fifth track). 
Abbreviations: gAPDh, glyceraldehyde-3-phosphate dehydrogenase; As-ODN, 
antisense oligodeoxynucleotides; Fe3O4, magnetic iron oxide; hcg, human chorionic 
gonadotropin.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 4 Fluorescence intensity in different cells
Groups Fluorescence intensity
Jeg-3 cells 26.57 ± 2.38
JAr cells 26.35 ± 2.27
rL95-2 cells 17.24 ± 1.06
hela cells 16.91 ± 1.51
hepg2 cells 13.26 ± 1.20
Lovo cells 13.77 ± 1.18
12 34
Figure 4 electrophoresis of simple gAPDh As-ODN (second track), nonaldehyde 
Fe3O4-dextran-anti-β-hcg-gAPDh As-ODN (third track), and aldehyde Fe3O4-
dextran-anti-β-hcg-gAPDh As-ODN (fourth track) that has been digested by 
DNase I. 
Abbreviations: gAPDh, glyceraldehyde-3-phosphate dehydrogenase; As-ODN, 
antisense oligodeoxynucleotides; Fe3O4, magnetic iron oxide; hcg, human chorionic 
gonadotropin; DNase I, deoxyribonuclease I.
groups. According to the Schiff reaction, aldehyde dextran-
coated iron oxide nanoparticles combine with anti-β-HCG 
monoclonal antibody and form stable products. BSA is then 
used to block the surplus hydroxyl groups (Figure 5).
In this study, Fe3O4-dextran-anti-β-HCG nanoparticles 
with an average diameter of 75.5 nm were synthesized. 
The results indicate that the magnetic nanoparticles, which 
have a diameter of ,100 nm, can take therapeutic genes 
into host cells. Moreover, nanoparticles can be targeted to 
specific tissues when guided by a magnet.7 At the same time, 
dextran-coated Fe3O4-dextran-anti-β-HCG nanoparticles can 
escape from the reticuloendothelial system and disperse in a 
fluid medium. These characteristics can help nanoparticles 
prolong the half-life, and this kind of stability also suggests 
Table  3  Fluorescence  intensity  of  nanoparticle  mixtures  in 
Jeg-3 cells
Groups Fluorescence intensity
I. control group   3.31 ± 0.37
II. Fe3O4-dextran-anti-β-hcg  
nanoparticle complexes
  9.69 ± 0.81
III. gAPDh As-ODN   8.41 ± 0.72
IV. Fe3O4-dextran-anti-β-hcg-gAPDh  
As-ODN complexes
26.57 ± 2.38
V. Liposome-gAPDh As-ODN  
complexes
15.36 ± 1.25
Abbreviations: gAPDh, glyceraldehyde-3-phosphate dehydrogenase; As-ODN, 
antisense  oligodeoxynucleotides;  hcg,  human  chorionic  gonadotropin;  Fe3O4, 
magnetic iron oxide.
that Fe3O4-dextran-anti-β-HCG nanoparticles can be used 
as gene vectors.
Biocompatibility of Fe3O4-dextran- 
anti-β-hcg nanoparticles
Having a safe gene carrier is very important for gene therapy. 
Studies have confirmed that iron-containing fluids have 
favorable biocompatibility. Unutilized iron is discharged 
by skin, gallbladder, and kidney.8,9 The biocompatibility of 
Fe3O4 particles is improved further with a dextran coating.
In this study, it was found that when the concentration 
of Fe3+ is ,37.5 µg/mL, nanoparticles were not toxic to 
choriocarcinoma cells.
Immunoreactivity of Fe3O4-dextran- 
anti-β-hcg nanoparticles
It is important that the process of combining dextran-coated 
iron oxide nanoparticles with anti-β-HCG monoclonal anti-
body preserves the antibody activity. In this study, it was 
found that the transfection efficiency of anti-β-HCG monoclo-
nal antibody activity in aldehyde Fe3O4-dextran-anti-β-HCG 
nanoparticle is higher than 85%, whereas the transfection 
efficiency of anti-β-HCG monoclonal antibody activity in 
nonaldehyde Fe3O4-dextran-anti-β-HCG nanoparticle is 
about 13%. This indicates that nonaldehyde dextran-coated 
iron oxide nanoparticles do not effectively bind to antibodies, 
although it is feasible for aldehyde dextran coat iron oxide 
nanoparticles to preserve antibody activity. To study the inter-
actions between Fe3O4-dextran-anti-β-HCG nanoparticles 
and choriocarcinoma cells, indirect immunofluorescence was 
used. The results show that Fe3O4-dextran-anti-β-HCG nano-
particles can attach to choriocarcinoma cells tightly, indicating 
that these nanoparticles have excellent discrimination and 
potency with respect to choriocarcinoma cells.
capability of Fe3O4-dextran-anti-β-hcg 
nanoparticle as a gene vector
The surface potential of Fe3O4-dextran nanoparticle is 
close to neutral, although the surrounding environment can International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Dovepress
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Figure 5 Theory of how Fe3O4-dextran-anti-β-hcg nanoparticles are prepared. 
Abbreviations: Fe3O4, magnetic iron oxide; hcg, human chorionic gonadotropin; BsA, bovine serum albumin.
Table 5 Distribution of Fe3O4-dextran-anti-β-hcg nanoparticles in nude mice (mg/g)
Group Heart Liver Spleen Lung Kidney Choriocarcinoma tumor
I 0.614 ± 0.05 1.351 ± 0.16 0.753 ± 0.07 0.663 ± 0.04 0.356 ± 0.02 5.959 ± 0.38
II 0.598 ± 0.05 2.994 ± 0.19 1.805 ± 0.15 0.586 ± 0.05 0.394 ± 0.03 4.112 ± 0.39
III 0.718 ± 0.09 6.398 ± 0.65 2.991 ± 0.24 0.697 ± 0.07 0.297 ± 0.02 1.262 ± 0.11
Abbreviations: HCG, human chorionic gonadotropin; Fe3O4, magnetic iron oxide.
easily influence its zeta potential. In acidic conditions the 
zeta potential can become positive, making it possible for 
Fe3O4-dextran nanoparticles to bind with the negative surface 
potential of DNA. In alkaline conditions nanoparticle zeta 
potential can become negative, making it highly unfavorable 
for the nanoparticles to bind with DNA.10
The pH of extracellular fluid in human beings is 
7.35–7.45, an alkaline environment, so it is unlikely for 
Fe3O4-dextran nanoparticles to combine with naked DNA. 
In this study, DNA was linked with Fe3O4-dextran-anti- 
β-HCG nanoparticles using an oxidation–reduction reaction. 
Electrophoretic analysis indicated that after being oxidized 
by NaIO4, Fe3O4-dextran-anti-β-HCG nanoparticles obtain 
the ability to bind with DNA. The principle is similar to that 
of combining Fe3O4-dextran nanoparticles with anti-β-HCG 
monoclonal antibody. Using flow cytometry, it was also found 
that Fe3O4-dextran-anti-β-HCG nanoparticles can help DNA 
insert into JEG-3 cells. Moreover, the transfection efficiency 
of Fe3O4-dextran-anti-β-HCG nanoparticles is higher than 
that for liposomes. This may be due to the small, narrow 
diameter of Fe3O4-dextran-anti-β-HCG nanoparticles, which 
provides a large specific surface area to bind DNA.
If DNA is digested by nucleases, the transfection effi-
ciency will be reduced.11 As a gene vector, nanoparticles 
have the advantage of protecting DNA from nucleases.12 
Chavany et al13 reported that poly(alkyl cyanoacrylate) 
nanoparticles can protect oligonucleotides from nucleases. 
Cui and Mumper14 discovered that free ‘naked’ plasmid 
DNA (pDNA) was completely digested by serum nucleases, 
while the entrapped pDNA remained intact. Moreover, 
in vitro transfection studies in HepG2 cells showed that 
pullulan-coated nanoparticles resulted in enhanced luciferase 
expression, compared with both pDNA alone and uncoated 
nanoparticles. Nakada et al15 found that nanoparticles could 
partially protect pdT16 against degradation in the plasma 
and in the liver 5 min after administration, whereas free oli-
gonucleotide was totally degraded. In this study, it was also 
found that Fe3O4-dextran-anti-β-HCG nanoparticles protect 
GAPDH AS-ODN from DNase I. This result is similar to 
research findings by Xiang et al.16,17 Rhaese et al18 reported 
that the reason for the protection is that DNA is surrounded 
by nanoparticles.
Target of Fe3O4-dextran-anti-β-hcg 
nanoparticle
Developing targeted gene vectors is a very active area of 
research in the field of genes therapy. In the absence of 
tissue-specific targeting, therapeutic genes will spread International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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to all organs through blood flow. This will not only reduce 
the drug concentrations in diseased organs, but also cause 
side effects. Researchers are, therefore, doing their best 
to increase drug concentrations in diseased organs, while 
decreasing the drug concentrations in other organs. As a gene 
vector, nanoparticles are of interest because they can impact 
distribution of DNA in the body due to targeting capabilities. 
Nanoparticle targeting can be divided into passive targeting 
and active targeting.6
In passive targeting, nanoparticles are taken into the reticu-
loendothelial system, such as the liver, spleen, and lymph, 
which is beneficial to diseases of the reticuloendothelial sys-
tem. However, when being used to treat tumors, nanoparticles 
are expected to assemble in the tumor itself, so the need to 
obtain active targeting becomes even more important.
Active targeting is subdivided into physical, chemical, and 
biological targeting. Physical and chemical targeting are real-
ized according to the pH, temperature, and magnetism of the 
nanoparticle, whereas biological targeting is realized according 
to the antigen and acceptor on the surface of nanoparticle.
To target choriocarcinomas, it is important to reduce the 
amount of nanoparticle that is absorbed by the reticuloen-
dothelial system. Fe3O4-dextran-anti-β-HCG nanoparticles 
that possess magnetic- and immune-targeting capabilities 
were prepared. To demonstrate nanoparticle targeting, the 
absorption of Fe3O4-dextran-anti-β-HCG-GAPDH AS-ODN 
in different cells was tested. The transfection efficiency of 
Fe3O4-dextran-anti-β-HCG nanoparticles in choriocarcinoma 
JEG-3 and JAR cells was found to be much higher than that 
in RL95-2, Hela, HepG2, and Lovo cells. This indicates that 
anti-β-HCG monoclonal antibody in Fe3O4-dextran-anti-
β-HCG nanoparticles combined specifically with β-HCG 
antigen in choriocarcinoma cells. In other words, these 
nanoparticles have characteristics of biological   targeting. 
However, it was also found that when using magnetic and 
immune targeting together, Fe3O4-dextran-anti-β-HCG 
nanoparticles are absorbed into the target reticuloendothe-
lial system and assemble in the choriocarcinoma tumor. 
  Furthermore, the combined effect of magnetic and immune 
targeting is stronger than that of magnetic targeting or 
immune targeting alone.
Conclusion
In summary, Fe3O4-dextran-anti-β-HCG nanoparticles 
represent an appropriate vector for gene therapy and dem-
onstrate strong resistance to degradation. They combine 
high transfection efficiency with good biocompatibility 
and low cytotoxicity. Because they can be targeted using 
  magnetic and antibody recognition mechanisms, they offer 
the   possibility for additional targeting strategies beyond 
those currently in use.
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